Connect with us

Technology

Implicity’s EVIDENCE-RM Study Demonstrates Marked Improvement in ICD Patient Outcomes

Published

on

Comprehensive analysis of real-world data shows significant clinical and medico-economic advantages of Implicity’s universal, alert-based remote monitoring platform

CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today unveiled new findings from its EVIDENCE-RM study¹. Leveraging extensive data from the French National Health Data System (SNDS), the study demonstrated clear clinical and medico-economic benefits associated with Implicity’s universal monitoring system (UMS) compared to conventional, manufacturer-specific systems, including Abbott, Biotronik, Boston Scientific, and Medtronic.

The study, recently published in Heart Rhythm, analyzed clinical outcomes and costs for over 69,000 patients with implantable cardioverter-defibrillators (ICDs) and defibrillators with cardiac resynchronization therapy (CRT-Ds). Patients remotely monitored using Implicity’s platform showed increased survival rates and a reduction in both the number and duration of all-cause and heart failure-related hospitalizations, resulting in substantial healthcare cost reductions. Key findings attributed to Implicity’s IM009² platform include:

26% reduction in mortality (HR, 0.74; 95% CI, 0.73–0.77; P=.001)4% decrease in HF hospitalizations, total corrected healthcare costs, and mean duration of hospitalization17.8% decrease in hospital-related costs, primarily driven by decreased costs in cardiovascular disease careIncremental Cost-Effectiveness Ratio (ICER) of approximately –$112 USD (-103€) per Day Alive and Out of Hospital (DAOH) based on the French Healthcare System

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure,” said Dr. Niraj Varma, Professor of Medicine and Director, Cardiac Pacing & Tachyarrhythmia Devices at the Cleveland Clinic. “The EVIDENCE-RM study clearly demonstrates that a universal monitoring solution operating alert-based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs. This is an important advancement in our ability to proactively manage patients with ICDs and CRTs.”

“These findings mark a pivotal moment in remote cardiac care and prove Implicity’s effectiveness with unparalleled clinical results,” stated Implicity CEO Dr. Arnaud Rosier. “A 26% reduction in mortality and better use of healthcare resources highlight the impact of universal remote monitoring, driven by AI, over fragmented manufacturer-specific systems. Implicity is committed to driving innovation so that every cardiac patient receives proactive, efficient care.”

For more information about Implicity and the EVIDENCE-RM study, please visit www.implicity.com.

About Implicity
Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI³ algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 100,000 patients in over 200 medical facilities across the US and Europe. To learn more, visit www.implicity.com

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

References

N. Varma et al., “Impact of a universal monitoring system (‘third party’) on outcomes of ICD patients: A nationwide study,” Heart Rhythm, 2024.IM009: 2021. Manufacturer: Implicity. IM009 is a software as a medical device (SaMD) intended to be used as an adjunct of a remote monitoring platform to follow-up target population patients. IM009 is compatible with devices with remote monitoring feature such as cardiac implantable electronic devices and connected weight scales. The three main intents of IM009 are to (1) label observations generated by medical devices according to predefined categories, (2) create clinically relevant observations for worsening atrial fibrillation and/or rapid weight gain in the context of heart failure, based on data recorded by the device and (3) label Atrial Fibrillation burden observations generated by cardiac implantable electronic device (CIED) as to be hidden or relevant for health care provider based on patient’s anticoagulation status. Hence, IM009 is designed to reduce the workload burden of healthcare providers/professionals in charge of reviewing the observations received from the patients’ devices. IM009 is not intended for use in life supporting or sustaining systems or Alarm devices and as a solely means of diagnosis. It is offered to healthcare providers/professionals on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Class I, according to Medical Device Directive 93/42/EEC. See the instructions for use for more information. Covered under the conditions defined in Article L. 162-52 of the French Social Security Code.IM007: 2021. ILR ECG ANALYZER created by Implicity is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQ11 Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42).
SignalHF FDA cleared Class II medical device and CE marked Class IIa (under MDR) medical device. Manufacturer: Implicity. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy.
See the instructions for use for more information.

Media Contact:
Sam Choinski
eMedia Junction
860-301-5058
samantha@emediajunction.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/implicitys-evidence-rm-study-demonstrates-marked-improvement-in-icd-patient-outcomes-302436176.html

SOURCE Implicity

Continue Reading

Technology

AmeriTrust Solutions Expands Point-of-Care Medicaid Application Support to All 50 States

Published

on

By

Available today, the platform gives hospitals and RCM partners a practical way to help eligible patients pursue coverage without a major IT project.

WASHINGTON, Oct. 22, 2026 /PRNewswire/ — AmeriTrust Solutions today announced that its Medicaid application platform is available across all 50 U.S. states. As hospitals and revenue cycle management (RCM) partners prepare for Medicaid changes under H.R.1, the platform gives them a practical way to help eligible patients pursue coverage and address uncompensated care at the point of care.

The platform addresses a source of uncompensated care that begins before billing: patients who may qualify for Medicaid but never complete an application. By simplifying the process when the need for coverage is immediate, AmeriTrust Solutions helps patients overcome application barriers and gives hospitals a path to reimbursement for care that might otherwise be written off.

The scale of the problem is substantial: U.S. community hospitals provided $42.7 billion in uncompensated care in 2020, according to the American Hospital Association.

Uninsured encounters are often written off as uncompensated care, even when patients may qualify for Medicaid. Long applications, confusing questions and information patients struggle to gather can stand between them and coverage, leaving hospitals without payment for care that could otherwise qualify for reimbursement.

“Hospitals already know what uncompensated care is costing them,” said Peter Justen, founder and CEO of AmeriTrust Solutions. “They need a practical way to help eligible patients get covered and create a path to payment for the care they provide. That starts with an application patients can actually finish.”

AmeriTrust Solutions uses verified third-party data to prefill available information and plain-language questions to guide patients through what remains. Patients review and certify their information before submission through the state’s existing process. The state makes every eligibility decision.

Available today, the platform is designed for straightforward deployment alongside existing hospital workflows, without a major IT project or replacement of state eligibility systems. Hospitals can begin submitting applications as soon as the platform is live, creating the potential for Medicaid reimbursement within weeks, depending on state eligibility decisions and claims processing. Hospitals can offer the experience under their own brand, giving existing teams a straightforward way to help patients complete applications at intake or the bedside.

RCM partners can add this capability to their hospital offering without developing Medicaid application technology internally. That gives them another way to support hospital clients serving uninsured and self-pay patients, with a focus on helping more applications reach submission.

As healthcare organizations evaluate AI and other new technologies, AmeriTrust Solutions puts the emphasis on a clear, guided application process and the value it can deliver. The platform uses verified information, relevant questions and applicant review to make a complex administrative task more manageable.

“The questions hospital leaders are asking are straightforward: What will this do for us, and how soon can we put it to work?” Justen said. “Our focus is helping patients complete applications now, so hospitals can begin addressing the coverage gaps that contribute to uncompensated care.”

Hospitals and RCM partners can learn more about the platform and discuss deployment at ameritrustsolutions.com/.

About AmeriTrust Solutions
AmeriTrust Solutions helps hospitals and RCM partners reduce uncompensated care by simplifying Medicaid applications at the point of care. Verified data prefill and guided questions help patients complete more accurate applications for submission through existing state eligibility processes. By reducing administrative burden and helping eligible patients access coverage, the company creates a clearer path to reimbursement—supporting rural hospital financial stability and helping preserve local access to care. Visit https://ameritrustsolutions.com/

Media contact
Tina Burgess
AmeriTrust Solutions
(202) 770-0272
pr@ameritrustsolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ameritrust-solutions-expands-point-of-care-medicaid-application-support-to-all-50-states-302917246.html

SOURCE AmeriTrust Solutions

Continue Reading

Technology

University of Phoenix highlights career-focused, transfer credit-friendly degree programs

Published

on

By

University data highlights affordability as students apply transfer credits toward business, management, healthcare, technology and other career-focused degree programs while reducing education costs

PHOENIX, Oct. 22, 2026 /PRNewswire/ — University of Phoenix is recognizing National Transfer Student Week by highlighting the degree programs receiving the highest volumes of transfer credits, demonstrating how adult learners are benefiting from affordability, transparency and certainty as they apply previously earned academic credit toward career-focused degrees. Many of these programs align with occupational fields projected for growth by the U.S. Bureau of Labor Statistics, underscoring how students are building on prior academic achievements while pursuing educational pathways connected to workforce needs.

According to University transfer-credit data for the past year, students applied more than 525,000 accepted transfer credits to the Bachelor of Science in Management program and more than 275,000 accepted transfer credits to the Bachelor of Science in Business program. University data also shows associate and bachelor students saved an average of more than $12,010 through transferred credits, excluding military students, underscoring the role transfer pathways can play in making higher education more affordable.

“Transfer credit can help students do more than save time and money,” said Devin Andrews, vice president, Office of Admissions and Evaluations. “It can help them continue making progress toward degrees that align with their professional goals. By recognizing eligible transfer credit, we help students build on what they have already accomplished and focus on the education and skills needed for the next phase of their careers.”

As University of Phoenix celebrates its 50th anniversary in 2026, the institution is reflecting five decades of helping working adults build on previous academic achievement and professional experience rather than start over. Today, transfer-credit pathways remain an important part of that mission, helping eligible students reduce costs while pursuing degrees aligned with career goals.

Students apply transfer credits across career-focused degree programs

University transfer-credit data shows students are applying significant volumes of transfer credit toward degree programs aligned with business, management, healthcare, public service and technology careers.

Programs receiving the highest volumes of accepted transfer credits include:

Bachelor of Science in Management: 525,085 accepted transfer credits and 447,622 applied transfer credits.Bachelor of Science in Business: 275,745 accepted transfer credits and 243,281 applied transfer credits.Bachelor of Science in Health Administration: 165,159 accepted transfer credits.Bachelor of Science in Criminal Justice Administration: 159,810 accepted transfer credits and 139,898 applied transfer credits.Bachelor of Science in Information Technology: 140,604 accepted transfer credits.Bachelor of Science in Social Work: 135,583 accepted transfer credits.

These programs represent areas where students are frequently building on previously earned academic credits as they continue toward degree completion and career goals.

University of Phoenix transfer student Joshua Barron decided to earn his degree while working full time and raising his child. “I have always had a goal of earning my bachelor’s degree,” said Barron, who came to the University with previous college credit. “I transferred credits from another college and used self-paced provider options to accelerate my progress. What started as a goal became a clear path toward achieving the degree I wanted for my future.”

Affordable degree pathways align with growing workforce needs

Several of the University’s most popular transfer-friendly programs align with occupations projected by the U.S. Bureau of Labor Statistics (BLS) to experience faster-than-average employment growth through 2034. Management occupations, Healthcare occupations, and Information Technology occupations all fall into high-growth categories according to BLS projections.

Learn more about transfer-credit opportunities

Students interested in learning how previously earned credits may apply toward a degree program can learn more here.

About University of Phoenix

University of Phoenix is Built for Real Life. 50 Years Strong. The University innovates to help working adults enhance their careers and develop skills in a rapidly changing world through flexible online learning, relevant courses, academic AI pillars, and skills-mapped curriculum for associate, bachelor’s and master’s degree programs. Active students and alumni have access to Career Services for Life® resources including career guidance and tools. For more information, visit phoenix.edu.

View original content to download multimedia:https://www.prnewswire.com/news-releases/university-of-phoenix-highlights-career-focused-transfer-credit-friendly-degree-programs-302917249.html

SOURCE University of Phoenix

Continue Reading

Technology

/C O R R E C T I O N – Verisave/

Published

on

By

In the news release, Verisave appoints Payments Veteran Chris Lefebvre as Chief Executive Officer to Drive Product Development and Growth, issued 22-Oct-2026 by Verisave over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Verisave appoints Payments Veteran Chris Lefebvre as Chief Executive Officer to Drive Product Development and Growth

SALT LAKE CITY, Oct. 22, 2026 /PRNewswire/ — Verisave, a leading provider of payments optimization solutions, today announced the appointment of Chris Lefebvre as Chief Executive Officer, effective October 1, 2026. Lefebvre, who joins from Fiserv, succeeds Jeremy Layton, who will transition into the role of Founder and Chief Commercial Officer to ensure strategic continuity.

Lefebvre brings more than 30 years of executive leadership across payments, financial services and technology, with a track record of guiding companies through growth, transformation and successful exits. He led financial services for a major retailer and was selected to serve on the Merchant Advisory Board for the card networks. As COO of BankServ, he led the company’s national expansion and its successful exit. Lefebvre has since held C-suite roles at eCommerce sales and marketing companies, after which he founded CRC, a management and strategy consulting firm serving regulated companies in healthcare, energy and financial services. Most recently, he served as Global Head of Relationship Management for Grocery, Petroleum, and Technology at Fiserv, and was instrumental in reshaping their client engagement strategy.

“I am extremely proud of the work Verisave has done over the years,” said Jeremy Layton, Verisave Founder and Chief Commercial Officer. “I am confident in our ability to continue bringing solutions and transparency to an industry that is largely unregulated and highly complex. Our clients increasingly need better solutions to control costs and manage their payments proactively. Chris brings deep payments expertise and a track record of building products and solutions around this need.”

“Verisave has built something rare: a trusted platform that delivers real and measurable value for its clients,” said Chris Lefebvre. “What drew me to the role is how much opportunity lies ahead, both in deepening our core solutions and expanding our reach across the broader financial ecosystem. I’m energized by the prospect of working with such a talented team as we look to accelerate Verisave’s growth and bring even greater value to our clients.”

About Verisave
Verisave is a payments optimization and consultancy firm, specializing in merchant account, payments stack, processing fee, and interchange fee solutions. Verisave identifies wasted spend and inefficiencies within the payments operations and merchant account settings, bringing significant direct and operational cost savings to clients. Headquartered in Salt Lake City, the company is backed by Ceto Capital. Learn more at verisave.com

Media Contact:
Samuel Barber
sam@pitchr.ai

Correction: A headshot of Chris Lefebvre has been added.

View original content to download multimedia:https://www.prnewswire.com/news-releases/verisave-appoints-payments-veteran-chris-lefebvre-as-chief-executive-officer-to-drive-product-development-and-growth-302917253.html

SOURCE Verisave

Continue Reading

Trending